In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Editorial Advisory Board
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Guidelines for Contributors
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

Percentage of Assured Money Vs. Total Potential Value in Pre-Commercial Stage Licensings, '92-'94

Executive Summary

In our statistical review, we chart the variation, year by year, in the average amount of money guaranteed to the licenser of a pre-commercial stage product as a percentage of the total potential value of the deal. It's been falling.

You may also be interested in...



Ireland Embarks On New Stage Of Drug Verification System

The bedding-in period is ending for Europe’s one-year-old system for preventing the circulation of fake medicines, and the scheme is gearing up for a more fully operational stage. 

DDD Bringing New Life To UK’s Baby-Care Category

DDD Ltd's global marketing director Katy Holder tells HBW Insight how the company is looking to carve out a niche in the UK's baby-care market with naturally derived ingredients and family-friendly product portfolios. 

Upsher-Smith Launches Three New Generics

Upsher-Smith has strengthened its US generics portfolio with three new launches that will compete in a combined market worth nearly $102.5m.

Table

View full table

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

IV000091

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By